Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News VolitionRX Ltd VNRX

Healthcare Medical Instruments & Supplies

VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:VNRX)

VolitionRx Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full

PR Newswire March 23, 2016

VolitionRx Announces Pricing of Public Offering of Common Stock

PR Newswire March 18, 2016

VolitionRx Announces Proposed Public Offering of Common Stock

PR Newswire March 17, 2016

VolitionRx Announces Full Year 2015 Financial Results and Business Update

PR Newswire March 11, 2016

VolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET

PR Newswire March 9, 2016

Preliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease

PR Newswire March 9, 2016

VolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ® Blood Test

Press Releases February 17, 2016

VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection

PR Newswire February 4, 2016

VolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK

PR Newswire February 2, 2016

VolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests

PR Newswire January 28, 2016

VolitionRx Releases Annual Shareholder Update Letter

PR Newswire January 13, 2016

VolitionRx Announces Dr. Jason Terrell's Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations

PR Newswire January 5, 2016

VolitionRx Granted Its Third U.S. Patent

PR Newswire January 4, 2016

VolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study

PR Newswire December 8, 2015

VolitionRx to Present at LD Micro Conference on December 3 in Los Angeles

PR Newswire November 30, 2015

VolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy

PR Newswire November 19, 2015

VolitionRx to Present at Two Conferences in November

PR Newswire November 12, 2015

VolitionRx Announces Third Quarter 2015 Financial Results and Business Update

PR Newswire November 4, 2015

VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET

PR Newswire October 30, 2015

VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study

PR Newswire October 22, 2015

Featured News Links

Options Trading for Retiring: Key Strategies in Balancing Retirement Income

One Property, One Focus on Advancing this Gold Project in Ontario